Skip to main content
Premium Trial:

Request an Annual Quote

FDA Licenses GeneGo s MetaCore Data Analysis Platform

NEW YORK, Oct. 10 (GenomeWeb News) - GeneGo has licensed its MetaCore data analysis platform to the US Food and Drug Administration for research and reviewing genomics data, the St. Joseph, Mich.-based company said today.


Under the agreement, GeneGo will integrate MetaCore with the FDA's ArrayTrack microarray analysis software and make it available to FDA researchers.


"Since MetaCore is already being applied in drug discovery by our pharmaceutical customers for a couple of years now, it is logical that it will also be used on the regulatory side as well," said GeneGo vice president of business development Julie Bryant in a company statement.


MetaCore allows researchers to visualize, map, and network several types of data, including gene expression, RNAi, proteomic, metabolomic, SAGE and SNP data.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.